Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Health Canada approves Novavax Inc's (NASDAQ: NVAX) Nuvaxovid COVID-19 Vaccine in individuals 18 years of age and older.  The vaccine, also known as NVX-CoV2373, is the first protein-based vaccine authorized for use in Canada.

Novavax's COVID-19 Vaccine Scores Canadian Approval

Nuvaxovid, a protein-based Covid vaccine, could help reduce hesitancy among people suspicious of mRNA vaccine technology.

Canada Authorizes Novavax's Non-MRNA Covid Vaccine For Use In Adults

Shares of Novavax Inc. NVAX, +1.05% gained 1.8% in trading on Thursday after the company said its COVID-19 vaccine has been authorized by Health Canada. Canada has already ordered 52 million doses of Novavax's vaccine, and the contract includes the option to order an additional 24 million doses.

Novavax's COVID-19 vaccine is authorized in Canada

Nuvaxovid™ is the first protein-based COVID-19 vaccine authorized for use in Canada GAITHERSBURG, Md., Feb. 17, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has granted authorization for Nuvaxovid™ COVID-19 Vaccine (Recombinant protein, Adjuvanted) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.

Health Canada Authorizes Novavax COVID-19 Vaccine

Etsy

Roku

If select analysts are correct, these rapidly growing companies could bounce back big time.

3 Supercharged Growth Stocks With 126% to 248% Upside, According to Wall Street

Novavax (NVAX) closed the most recent trading day at $86.55, moving -0.67% from the previous trading session.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

A recent poll supports Novavax's Covid treatment in the United States, but the vote on today's NVAX stock price chart warns against buying. The post Novavax Stock Is at Risk Despite Positive Poll Results appeared first on InvestorPlace.

Novavax Stock Is at Risk Despite Positive Poll Results

Patient investors should wait for NVAX stock to hit another low or for the FDA to approve its Covid-19 vaccine before investing. The post Novavax Just Can't Get it Together appeared first on InvestorPlace.

Novavax Just Can't Get it Together

Novavax's milestone means investors can now exhale.

Novavax Investors Can Finally Breathe a Sigh of Relief

On paper it's possible, but don't hold your breath.

Will Novavax Stock Ever Hit $300 Again?

Gilead Sciences

Vertex Pharmaceuticals

Their long-term prospects appear to be bright.

3 Biotech Stocks to Buy in February

NVAX stock has been derided as a ran in the vaccine race, avoid that narrative and remain optimistic because the best is ahead for Novavax. The post Novavax Stock Has Growth Ahead Whether It Missed the Boat or Not appeared first on InvestorPlace.

Novavax Stock Has Growth Ahead Whether It Missed the Boat or Not

Management is terrible at delivering on its promises and even good news has failed to translate into higher prices for NVAX stock. The post Why I'm Done With Novavax Stock appeared first on InvestorPlace.

Why I'm Done With Novavax Stock

The latest setback for NVAX stock is lower than expected delivery numbers for its Covid-19 vaccine. The longer it takes to get its vaccine into arms, the more it risks losing a critical advantage.

Shipment Delays Threaten the Best Advantage Novavax Has

Dynavax Technologies

Ocugen, Inc.

A broad stock market rebound and an encouraging survey appear to be boosting these vaccine stocks.

Why Novavax, Dynavax, and Ocugen Are All Rising Today

Can Novavax Stock Double in 2022?

GAITHERSBURG, Md., Feb. 14, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Singapore Health Sciences Authority (HSA) has issued interim authorization for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine

BioNTech SE

Moderna

Pfizer

A delay for Pfizer and BioNTech appears to be weighing on all vaccine stocks.

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Sliding Today

Novavax Inc has submitted an application to Switzerland's drugs regulator for the authorization of its COVID-19 vaccine in adults, the U.S. vaccine maker said on Monday.

Novavax applies for COVID-19 vaccine approval in Switzerland

GAITHERSBURG, Md., Feb. 14, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional marketing authorization (CMA) of NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant, for use in adults.

Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland

NVAX has received EUA for its COVID-19 vaccine in several countries.

Will Novavax Get Hit By Moderna Backdraft?

The company's coronavirus vaccine tests very well on adolescents.

Why Novavax Stock Got a Shot in the Arm Friday

Novavax's (NVAX) COVID vaccine achieves 80% overall efficacy in a phase III study in adolescents aged between 12 and 17.

Novavax's (NVAX) COVID Vaccine Achieves Study Goal in Kids

GAITHERSBURG, Md., Feb. 11, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.

Novavax to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference

Shares of Novavax Inc. NVAX, -4.13% gained 2.5% in premarket trading on Friday, the day after the company said its experimental COVID-19 vaccine had an 80% efficacy rate in teens. The results stem from a Phase 3 clinical trial that occurred when delta was the most dominant strain of the virus.

News for Novavax Stock (NVAX)